LearnGlossaryMarketStocksSuperinvestorsSign in

NPCE

NeuroPace, Inc.

Healthcare · $469M market cap

Verdict

We can't put a fair value on NPCE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-35.2% a year✗
Sales growth18.1% a year✓
Free cash flow growth—?
Return on invested capital-24.7%✗

Follow NPCE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Becker Joel

CHIEF EXECUTIVE OFFICER · 2026-09-03

Tax withholding

$19K

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works